The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Maciejewska-Markiewicz, Dominika
    Stachowska, Ewa
    Hawrylkowicz, Viktoria
    Stachowska, Laura
    Prowans, Piotr
    BIOMOLECULES, 2021, 11 (07)
  • [32] Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
    Changez, Mah I. Kan
    Mubeen, Maryam
    Zehra, Monezahe
    Samnani, Inara
    Rasool, Aniqa Abdul
    Mohan, Anmol
    Ul Wara, Um
    Tejwaney, Usha
    Kumar, Vikash
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (09)
  • [33] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    不详
    GASTROENTEROLOGE, 2021, 16 (05): : 386 - 386
  • [34] A lipidomic analysis of non-alcoholic fatty liver disease (NAFLD)
    Puri, P.
    Baillie, R. A.
    Wiest, M.
    Mirshahi, F.
    Sanyal, A. J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S260 - S261
  • [35] Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Drzewoski, Jozef
    Szymczak-Pajor, Izabela
    Zieleniak, Andrzej
    Mikolajczyk-Solinska, Melania
    Kasznicki, Jacek
    Sliwinska, Agnieszka
    BIOMEDICINES, 2022, 10 (09)
  • [36] Antiepileptic drugs and non-alcoholic fatty liver disease (NAFLD)
    Waldmann, M
    Sturm, W
    Naser, A
    Unterberger, I
    Trinka, E
    Bauer, G
    Lechleitner, M
    Luef, G
    EPILEPSIA, 2004, 45 : 161 - 162
  • [37] Diagnosis and management of non-alcoholic fatty liver disease (NAFLD)
    Byrne, C. D.
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A2 - A2
  • [38] Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Rong, Li
    Zou, Junyan
    Ran, Wei
    Qi, Xiaohong
    Chen, Yaokai
    Cui, Hongjuan
    Guo, Jinjun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [39] Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
    Tomasiewicz, Krzysztof
    Flisiak, Robert
    Halota, Waldemar
    Jaroszewicz, Jerzy
    Lebensztejn, Dariusz
    Lisik, Wojciech
    Malkowski, Piotr
    Pawlowska, Malgorzata
    Piekarska, Anna
    Simon, Krzysztof
    Tronina, Olga
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 4 (03) : 153 - 157
  • [40] Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
    Park, Yongsoo
    Ko, Kyung Soo
    Rhee, Byoung Doo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)